GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
‘I see no real point in it’ – Employment lawyer questions need for equality bill
Andrew Borg Cardona says protection against discrimination is already very well provided for under existing legislation.
Aleander Balzan appointed CEO of the Foundation for Tomorrow’s Schools
He has served as a Policy Advisor within the Office of the Prime Minister and also headed the Secretariat of ...
Matthew Costa appointed CEO of the National Development and Social Fund
The Ministry also expresses its gratitude to Raymond Ellul for his service and contribution in leading the NDSF.
Antoinette Muscat appointed Chief Operating Officer at NM Group
'Looking forward to what's ahead!'
